Wednesday , October 18 2017
Home / Business News

Business News

AbbVie and Harpoon Therapeutics Enter Immuno-Oncology Research Collaboration

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have entered an immuno-oncology research collaboration. The goal of the collaboration is to incorporate …

Read More »

Lilly and CureVac Enter Global Collaboration to Develop mRNA Cancer Vaccines

INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer …

Read More »

Bristol-Myers Squibb Extends Partnership with Target PharmaSolutions for TARGET-NASH

CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement.  Bristol-Myers Squibb is committed to the discovery and development of medicines for fibrosis, including NASH. …

Read More »

Seattle Genetics Enters Two New Collaborations to Evaluating SGN-LIV1A in Triple Negative Breast Cancer

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ: SGEN) today announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer (TNBC). SGN-LIV1A is an investigational antibody-drug conjugate (ADC) that targets the cell surface protein LIV-1, which is expressed on multiple solid tumors including breast, prostate, melanoma, …

Read More »

Express Scripts Acquires eviCore for $3.6 Billion, Accelerating its Shift to Patient Benefit Management

LOUIS and BLUFFTON, S.C., Oct. 10, 2017 /PRNewswire/ — Express Scripts Holding Company (NASDAQ: ESRX) today announced that it has reached an agreement to acquire privately-held eviCore healthcare, the industry leader in evidence-based medical benefit management services, for $3.6 billion. Combining Express Scripts’ leading pharmacy benefit management offering and eviCore’s …

Read More »

Ligand to Acquire Crystal Bioscience, Gaining Complementary Antibody Technology

SAN DIEGO & EMERYVILLE, Calif.–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Crystal Bioscience, Inc. (Crystal) announce the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies. Under the terms of the agreement, Ligand will pay Crystal shareholders $25 million …

Read More »

Celgene and Nimbus Enter Immunology Alliance to Develop Programs for Autoimmune Disorders

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today the initiation of a long-term strategic alliance with Celgene Corporation (NASDAQ: CELG) in immunology. Under the terms of the agreement, Celgene will receive an option to acquire each program in the alliance …

Read More »

Amgen and CytomX Enter Immuno-Oncology Collaboration

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and CytomX Therapeutics, Inc., (NASDAQ: CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor …

Read More »

Merck Discontinues MK-3682B and MK-3682C Development Programs

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. This decision was made based on …

Read More »

Novartis and UC Berkeley Collaborate to Tackle ‘Undruggable’ Disease Targets

Basel, Switzerland, September 28, 2017 – Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.” “Novartis pioneers …

Read More »